​Continued from previous page.

Dr Toh Han Chong, Senior Consultant, Division of Medical Oncology, and Deputy Director, National Cancer Centre Singapore (NCCS), a member of the SingHealth group, shares more on the new cancer therapy.

Conventional treatment for cancer usually involves one or a combination of methods: surgery, chemotherapy and radiation as well as hormone therapy and targeted therapy.

A new cancer therapy has emerged that uses the patient's own immune system to destroy the cancer cells directly.


Grown in the laboratory using a patient’s own blood, T-cells are gaining traction as an important form of immunotherapy. Dr Toh describes them as the body’s fighting soldiers. These T-cells can be engineered to become very sophisticated highly-trained soldiers that can be developed to target protein(s) on the cancer cells, grown to very large numbers, sometimes in the billions, to be then reintroduced to the patient to specifically attack the cancer existing in the body.

Dr Toh said several studies have shown dramatic success of one particular form of T-cell therapy, that of the chimeric antigen receptor (CAR) T-cell therapy, against leukaemia that has become resistant to conventional treatment. After getting this therapy, many patients with acute leukaemia, who had no other treatment options available to them, became completely cancer-free and have remained cancer-free for some years now.

However, it is not yet clear if they have all been cured. Still, CAR T-cell therapy is being hailed as a major breakthrough in the treatment of leukaemia. Dr Toh’s own study group has been working on harnessing the body’s own T-cells and re-engineering them to attack viral proteins on virally-driven cancers such as nasopharyngeal cancer.


Antibodies are like guided missiles, homing in on cancer cells or the surrounding immune cells to effect their function of containing the cancer. They can either directly kill cancer cells or activate a patient’s immune system to fight the cancer. “New types of antibodies that activate the immune system to fight cancer (anti-PD1 and anti-PDL1) have been especially successful in melanoma (skin cancer) treatment. They are also looking exciting for lung cancer, Hodgkin’s lymphoma and other cancers such as bladder and gastric cancers,” said Dr Toh.


These signalling proteins produced by white blood cells help the immune system to recognise and destroy cancer cells. They include interferons, which help the immune system boost the ability of certain immune cells to attack cancer cells and slow their growth, and interleukins, which help those immune cells grow and divide more quickly in order to destroy the cancer.

Putting immunotherapy into perspective, Dr Toh said that like other treatments, it works well on some cancers and not others, and that even within a particular cancer, it works well for some patients and not others. The field is still evolving; globally, tremendous resources are now being poured in to assess the true benefit of different kinds of cancer immunotherapy on many types of cancer.

“Chemotherapy treatment goes back over 60 years and is a cornerstone in the treatment of many types of cancer. With radiotherapy, there’s going to be increasingly more accurate radiation therapy technology, and radiotherapy will undoubtedly continue to be a pillar in cancer therapy. So too for surgery which in many cases, is the crucial mode of treatment to eradicate cancer. These remain the standard bearers of cancer treatment, as well as targeted therapy and hormone therapy for some cancers. And now, we can add immunotherapy to the list.”

Ref: Q15